Expert Interview
Discussing the topline data from Lilly's SURMOUNT-OSA Phase 3 trial on tirzepatide for patients with Obstructive Sleep Apnea and the impact on the use of CPAP
Ticker(s): LLY, PHG, RMDInstitution: Johns Hopkins
- Medical Director, Johns Hopkins Sleep Disorders Center and Associate Professor of Neurology at JHU School of Medicine.
- Actively treats over 1,500 patients with OSA, 20-30 patients with Narcolepsy, and 40-50 patients with Idiopathic Hypersomnia.
- Research interests are in the area of sleep medicine, specifically investigating the co-morbid health consequences of chronic sleep deprivation.
Please describe your background and practice setting?
Added By: ben_adminWhat is the current standard of care for sleep apnea? Can you talk about you use of CPAP machines to date?
Added By: ben_adminWhat are your thoughts on the recent data presented in the NEJM on the effects of tirzepatide for OSA treatment?
Added By: ben_adminDo you think the use of tirzepatide will impact your usage of CPAP machines in the future?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
